Recruitment of CD103(+) dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy

Although a clinical breakthrough for cancer treatment, it remains that a minority of patients respond to checkpoint inhibitor (CPI) immunotherapy. The composition of tumor-infiltrating immune cells has been identified as a key factor influencing CPI therapy success. Thus, enhancing tumor immune cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Williford, John-Michael, Ishihara, Jun, Ishihara, Ako, Mansurov, Aslan, Hosseinchi, Peyman, Marchell, Tiffany M., Potin, Lambert, Swartz, Melody A., Hubbell, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905870/
https://www.ncbi.nlm.nih.gov/pubmed/31844672
http://dx.doi.org/10.1126/sciadv.aay1357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905870/
https://www.ncbi.nlm.nih.gov/pubmed/31844672
http://dx.doi.org/10.1126/sciadv.aay1357

Ejemplares similares